IRVINE, Calif.--(BUSINESS WIRE)-- <\/p>\n
Concluding a series of conference presentations in recent months, California Stem Cell (CSC) Medical Director and Principal Investigator Robert O. Dillman, M.D. will be delivering an oral presentation at todays Biotherapeutics & Stem Cell Processing Symposia in London, UK. The presentation will provide details and phase II clinical trial results from a promising therapy for the treatment of metastatic melanoma, recently acquired by CSC from Hoag Hospital in Newport Beach. In two previous presentations at both the AACR and ASCO conferences in Chicago, Dr. Dillman compared pooled data from this and two other phase II immunotherapies for the treatment of metastatic melanoma. <\/p>\n
Data pooled from three successive phase II trials were compared in order to determine the impact on overall survival rates of patient specific immunotherapies utilizing antigens from autologous cancer stem cells. Results demonstrated that autologous dendritic cells loaded with antigens from cancer stem cells significantly improved survival rates and time to recurrence when compared with treatments using irradiated cancer cells alone. 2-year overall survival rates tracked at 72%, as compared to 45% from the therapy using only irradiated cancer stem cells. 5-year median survivals of patients tracked over 50%, double that of any other current treatments. <\/p>\n
California Stem Cell acquired the entirety of Hoag Hospitals metastatic melanoma research program in October of 2011 and plans to initiate Phase III trials in the near future. <\/p>\n
About California Stem Cell <\/p>\n
California Stem Cell, Inc. (CSC) is an Irvine, CA based company which has developed proprietary methods to generate human stem cell lines, expand them to clinically and commercially useful numbers, and differentiate them at extremely high purity using fully-defined, proprietary media and GMP processes. CSC is able to supply its human cell populations to companies and institutions worldwide for use in the development of therapies, efficacy screening or the creation of toxicity profiles for candidate drugs, and experimental research tools. <\/p>\n
CSC is focused on the development of stem cell based therapies for spinal muscular atrophy (SMA), amyotrophic lateral sclerosis (ALS, or Lou Gehrigs Disease), and metastatic cancers. <\/p>\n
Follow us on Twitter: http:\/\/twitter.com\/castemcell<\/a> <\/p>\n<\/p>\n Here is the original post:<\/p>\n California Stem Cell Medical Director Robert O. Dillman, M.D. to Present Details, Phase II Trial Results of Melanoma ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" IRVINE, Calif.--(BUSINESS WIRE)-- Concluding a series of conference presentations in recent months, California Stem Cell (CSC) Medical Director and Principal Investigator Robert O. Dillman, M.D. will be delivering an oral presentation at todays Biotherapeutics & Stem Cell Processing Symposia in London, UK Continue reading